TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: International Dental Federation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual Rate of Decline in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 4-hour Urinary Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Risk Behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Resting anorectal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure of the urge to defecate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Measure (motor portion)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in fasting plasma ammonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean amplitude of glucose excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Density of nerve fibers in endometrial biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confirmed Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of a pigment epithelial detachment (PED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes of subretinal fluid (SRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Caries prevention effect of the sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Crestal Bone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Creatine Kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle slow troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Pruritus Events
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of breast imaging devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean bladder comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Improved Global Response Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Requirement for replacement of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in One Second (FEV1), Average Effect Over 22 - 26 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Financial toxicity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Acute Antibody Mediated Rejection (AAMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Best overall response rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of unprotected anal and vaginal sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Genotypic Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Exhibiting Treatment-Emergent Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SCORAD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 5-item Observer OPTION scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebrospinal Fluid (CSF) Abeta42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessor confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Walking Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Community Walking Performance Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Walking Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Walking Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bioequivalence measured by Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychosocial status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TB treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positioning accuracy and precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Antiretroviral Therapy (ART) Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of IOP-enhanced MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Rating Scale for Tremor (TRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to tumour progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Numeric pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maintenance in the Biering-Sorensen Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net change of Patient Perception of Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported cognitive failures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disability measured by Disabilities of the Arm, Shoulder, and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower Eyelid Steatoblepharon Severity (LESS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transfused parturients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in peripheral blood counts and differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in antigen expression on the leukemic blasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in measurable residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in chromosomal translocations and aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Ocular Axial Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness assessment by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessment by Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of alpha-synuclein aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Specific Quality of Life Scale (SS-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: transepithelial resistance (mucosal integrity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Clostridium Difficile Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of RSV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Integrated viral HIV-1 DNA in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Unintegrated viral HIV-1 DNA in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in lymphocyte activation markers in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acute Procedure Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Serious Adverse Events Related to the Procedure Through 7 Days
Endpoint domain: Adverse events/effects
Primary endpoint: PCa detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: incidence of xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Experienced Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Estimated Number of AECOPD With Sputum Containing Bacterial Pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall AECOPD Exacerbation Rate for Any and Specific Bacterial Pathogens in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of found and understood-if-found items
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ambulatory Extended Recovery (AXR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anti-Natalizumab Antibody Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Rolland Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Arterial stiffness measured by ultrasound derived index B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with serious ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ctau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity and Sensitivity of AI models
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: adverse event frequency and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Radium-223 Dichloride-/Placebo-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Radium-223 Dichloride-/Placebo-related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Radium-223 Dichloride-/Placebo-related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Upper limb range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite primary safety endpoints
Endpoint domain: Adverse events/effects
Primary endpoint: composite primary effectiveness endpoints
Endpoint domain: Physiological/clinical
Primary endpoint: Change in quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee joint function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Development of exudative AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ro resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Evaluation of neurological treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DNA damage response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor immune microenvironment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: skin flap healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognitive Assessment Task Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Survival characteristics
Endpoint domain: Mortality/survival
Primary endpoint: Change in regional ventilation at the first postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in regional ventilation at the third postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in self-reported shoulder function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recognition Memory Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with any serious adverse event (SAE), non-serious adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of preliminary clinical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-progression at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Alveolar-arterial Oxygen Gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eligible Patients With Positive Imaging Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in wound width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change of vancouver scar scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life as measured by the FACIT scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Crude Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: PROMIS CAT Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Numerical rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Live Birth Rate Per Started Cycle
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune profile of blast cells and immune effector cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Excessive physical load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of humor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Rankin Scale at Discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk-Adjusted Mortality Ratio
Endpoint domain: Mortality/survival
Primary endpoint: Time to Upper Limb Disability Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Subject incidence of treatment-emergent suicidal ideation and behavior as measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pulmonary vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: birth weight ≥ 90th percentile for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: neonatal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: birth injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Behavioral Assessment System for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trunk Impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Jamar/Handheld micro Force Evaluation and Testing 2 (microFET2) Dynamometers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of face and neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute sinusitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microbiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: FAOS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ-5D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tegner activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity of the Omron WheezeScan device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: specificity of the Omron WheezeScan device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in maximal dyskinesia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: ductal closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance on the Looking-While-Listening Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of Liver Disease
Endpoint domain: Mortality/survival
Primary endpoint: Increase in Ishak Fibrosis Score by 2 Points or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient reported symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Quality of Life according to QLQ-C30 Summary scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the number of triggered alerts by the tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of viable cells in resected peritoneal deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Epithelium analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASV Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurocognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Multiple dose drug tolerability
Endpoint domain: Adverse events/effects